We had the pleasure to meet with our Editor-in-Chief, Professor Peter C Taylor (University of Oxford, Oxford, UK) who gave us some of the key highlights from this year’s European Congress of Rheumatology meeting, 2-5 June 2021.
- What were the highlights of this year’s EULAR meeting? (0:11)
Disclosures: Peter C Taylor reports receiving: Research grants from Celgene, Galapagos, Gilead and Lilly; and consultation fees from AbbVie, BMS, Biogen, Fresenius, Galapagos, Gilead, GlaxoSmithKline, Janssen, Lilly, Nordic Pharma, Pfizer, Roche, Sanofi, and UCB
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Victoria Jones.
Filmed as a highlight of EULAR 2021 (Virtual).
Share this Video
Related Videos In Psoriatic Arthritis
Michaela Koehm, ACR 2021: Methotrexate Effect on bDMARDs in the Treatment of Active PsA
We were delighted to speak with Dr. Michaela Koehm (Goethe University, Frankfurt am Main, Germany) to discuss her trial investigating the effect of methotrexate on ustekinumab treatment for active psoriatic arthritis. The abstract ‘Neither Add-on nor Withdrawal of Methotrexate Impacts Efficacy of IL12/23 Inhibition in Active PsA: Data from a Multicenter Investigator-initiated Randomized Placebo-controlled Clinical […]
Atul Deodhar, ACR 2021: Efficacy of Deucravacitinib by Baseline DMARD Use in Psoriatic Arthritis
It was a pleasure to discuss with Prof. Atul Deodhar (Oregon Health & Science University, Portland, OR, USA) the results from the further exploratory analysis of the phase 2 trial (NCT03881059) investigating the TYK2 inhibitor, deucravacitinib, in patients with psoriatic arthritis treated with and without background conventional synthetic DMARDs. This information is brought to you […]
Merav Lidar, ACR 2021: Efficacy and Safety of Risankizumab in Psoriatic Arthritis
Prof. Merav Lidar (Sheba Medical Center, Tel Hashomer, Israel) kindly took the time to discuss the 24-week efficacy and safety results from the KEEPsaKE2 trial (NCT03671148). This phase 3 randomized, double-blind trial investigated the humanized immunoglobulin G1 monoclonal antibody, risankizumab, in adults with psoriatic arthritis (PsA). This information is brought to you by Touch Medical […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!